Hepa-Merz (Ornithine Aspartate)

Ornithine aspartate supplies key substrates for the urea cycle and for glutamine synthesis. This enhances the conversion of toxic ammonia into urea and glutamine, facilitating its removal from the bloodstream and supporting hepatic metabolic processes.

The appropriate dose of Hepa-Merz is determined by the prescribing healthcare professional based on the individual’s clinical condition, liver function status, and any concomitant therapies. Patients should follow the prescriber’s instructions precisely.

Safety data for ornithine aspartate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Hepa-Merz.

To order Hepa-Merz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with agents such as lactulose or rifaximin, ornithine aspartate works by directly enhancing ammonia detoxification through metabolic pathways rather than altering gut flora. It may be used alone or in combination with other therapies, depending on the clinical strategy chosen by the physician.

Store Hepa-Merz at ambient temperature, below 25 °C, in the original container. Protect the tablets from moisture, direct sunlight and extreme heat to maintain product stability throughout its shelf life.

Hepa-Merz is taken orally, usually with a glass of water. It can be taken with or without food, unless the prescribing clinician advises otherwise. The exact timing and frequency should follow the healthcare professional’s directions.

Serious risks, although rare, include severe allergic reactions such as anaphylaxis, hepatic decompensation, marked elevation of liver enzymes, and renal impairment. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, difficulty breathing, jaundice or sudden loss of kidney function.

Individuals with known hypersensitivity to ornithine aspartate or any excipients in the tablet should avoid Hepa-Merz. Patients with severe hepatic failure, uncontrolled renal disease, or those taking contraindicated medications should consult their physician before initiating therapy.